Photo by Akili Interactive.
April 9, 2021
Akili Interactive, the maker of the FDA De Novo-authorized digital therapeutic EndeavorRx, will be testing its video game ADHD treatment as a potential treatment for cognitive impairments in COVID-19 survivors.
Through collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center, Akili will conduct two separate randomized, controlled clinical...
(Image courtesy of Akili Interactive)
March 29, 2021
Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment.
"These results increase the...
September 17, 2020
The increased adoption of virtual care technologies during the COVID-19 public health emergency is fairly well documented by this point, but a widespread embrace of health technologies is providing a similar upswell on individual niches within the digital health landscape.
One such group of beneficiaries are the companies working to develop, validate and distribute digital therapeutics. Speaking...
June 15, 2020
After years of waiting, Akili Interactive has finally received FDA De Novo marketing authorization for EndeavorRx, its video-game digital therapeutic for children aged 8 to 12 years with ADHD.
This is the first game-based therapeutic that the FDA has greenlit for any condition, the regulatory agency noted in its announcement. It is also the first authorization for Akili, which has a handful of...
April 22, 2020
Less than a week after FDA opened the faucet for digital health products treating psychiatric conditions during the COVID-19 health crisis, Akili has fast-tracked and released its approval-pending digital therapeutic for children with ADHD.
Now known as Endeavor and flanked by a symptom tracker and caretaker support line, the video game-like app will be provided at no cost for a limited time to...
February 24, 2020
A full transcript of STARS-ADHD — the pivotal trial of Akili Interactive’s video game-like pediatric attention deficit treatment — has been published in The Lancet Digital Health journal, providing onlookers a clear view of data fueling the digital therapeutic company’s pending FDA submission.
The writeup echoes topline findings first unveiled by the company in December 2017: compared to a...
January 15, 2020
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error.
Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication.
Called the ...
September 25, 2019
There’s no denying that digital therapeutics look and feel different than traditional medications. Instead of popping open a medication bottle, users are logging into an app to access treatment. But the differences don’t stop at the look. While the risk of toxicity is an ever-looming question in the pharma space, the same isn’t true for digital solutions.
Stakeholders at the digital therapeutics...
April 11, 2019
This morning, digital therapeutics maker Akili Interactive announced it has added a new CFO and general counsel to its ranks.
The former is Santosh Shanbhag, a senior executive who boasts a prior VP role at Vertex Pharmaceutical as well as positions at Capgemini Consulting and Texas Instruments. Jacqueline Studer, on the other hand, served as CVP, general counsel and secretary at IDEXX...
Left to right: Dr. Daniel Kraft, Fitbit's Any McDonough, Verily's Dr. Jess Mega and Akili's Eddie Martucci chat on stage at CES 2019’s Digital Health Summit
January 9, 2019
Digital therapeutics are a nascent corner of the healthcare technology industry. With few precedents available outside of novel drugs or medical devices, it would make sense that Pear Therapeutics, Proteus and other digital therapeutics companies furthest along the regulatory pipeline align themselves with industry partners well versed in selling and supporting a medical product.
As such, it came...